PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease


To quantify the short (24 weeks), medium (one year), and long-term (five year) effects of PCSK9 MABs on lipid parameters and CVD risk.


To quantify the safety of PCSK9 MABs, specifically focusing on the incidence of type 2 diabetes, cognitive function, and cancer. Additionally, we will determine if treatment should be tailored to certain patient subgroups that are more or less likely to benefit from PCSK9 MABs.

This is a protocol.